About Fluicell
Fluicell was founded in 2012, based on a vision to push the boundaries of science. Using our unique single-cell technology, we unlock new ways of studying cells in their native environment. Fluicell's research solutions has made it possible for scientists to study biological processes at a whole new level of detail and have been a central part of many significant research breakthroughs.
Today, we are bringing our innovative and visionary mindset to the area of regenerative medicine, changing the way we treat diseases. With our microfluidic bioprinting technology and our tissue engineering platform Nexocyte, we are creating groundbreaking tissue-based solutions for regenerative medicine and drug development, targeting serious diseases that affect the lives of millions of people around the world.
Our vision
Fluicell’s vision is to change the lives of millions of people worldwide living with chronic serious illnesses by developing tissue therapeutics that transform how we treat disease. With our high-precision tissue production platform, we aim to push the boundaries of regenerative medicine and drug development – one cell at a time.
We are Fluicell
The people at Fluicell is a the core of everything we do. With a team creative and innovative researchers and dedicated management and board with extensive experience from research, drug development and entrepreneurship, we work together to defeat serious disease.
Latest news
Careers
Fluicell is an innovative life science company that empowers scientists worldwide by providing cutting-edge research tools with an emphasis on single-cell biology. The work that we do is characterized by a spirit of openness and curiosity. If you enjoy working in a collaborative and creative environment at the forefront of technological development in life science, then Fluicell is the right place for you.
We are always on the lookout for talented people to join our team. Please submit your resume to info@fluicell.com
Read more
platform
Learn more about Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.
Pipeline
Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.
Investing in fluicell
On this page you can find press releases, annual reports, investor presentations and other information regarding Fluicell and the Fluicell share.
Partner with us!
Learn about what we hope to achieve in partnership with innovation-driven pharmaceutical companies. Have questions or interested in exploring a collaboration? Get in touch.